Literature DB >> 15209377

PI 3-kinase, Akt and cell survival.

Julian Downward1.   

Abstract

Phosphoinositide 3-OH kinase (PI 3-kinase) provides cells with a survival signal that allows them to withstand apoptotic stimuli. Many tumour cells display elevated levels of PI 3-kinase products as a result of deletion of the phosphatase PTEN, activation of Ras or expression of autocrine growth factors. As a result they are relatively resistant to apoptosis. The mechanisms for PI 3-kinase survival signalling are becoming clear. The principal mediator is Akt, a PI 3-kinase activated protein kinase. Akt has direct effects on the apoptosis machinery, for example targeting the pro-apoptotic Bcl-2 related protein, BAD. It also affects the transcriptional response to apoptotic stimuli, for example by acting on Forkhead factors and also influence the activity of the p53 family. In addition, novel connections between the metabolic effects of Akt and its control of survival have recently been made.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15209377     DOI: 10.1016/j.semcdb.2004.01.002

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  227 in total

1.  AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth.

Authors:  Sang Ryong Kim; Tatyana Kareva; Olga Yarygina; Nikolai Kholodilov; Robert E Burke
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 2.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

3.  Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Scott J Cotler; Nissim Hay; Hui Xie; Mei Ling Chen; Pei Zhang Xu; Thomas J Layden; Grace Guzman
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

4.  Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation.

Authors:  Michael P Scheid; Michael Parsons; James R Woodgett
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

5.  FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Authors:  Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

6.  STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.

Authors:  Christian Moser; Petra Ruemmele; Sebastian Gehmert; Hedwig Schenk; Marina P Kreutz; Maria E Mycielska; Christina Hackl; Alexander Kroemer; Andreas A Schnitzbauer; Oliver Stoeltzing; Hans J Schlitt; Edward K Geissler; Sven A Lang
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

Review 7.  The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.

Authors:  Yiwei Li; Vay Liang W Go; Fazlul H Sarkar
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

8.  Gene-ethanol interactions underlying fetal alcohol spectrum disorders.

Authors:  Neil McCarthy; Johann K Eberhart
Journal:  Cell Mol Life Sci       Date:  2014-02-20       Impact factor: 9.261

Review 9.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

10.  C3aR inhibition reduces neurodegeneration in experimental lupus.

Authors:  A Jacob; L Bao; J Brorson; R J Quigg; J J Alexander
Journal:  Lupus       Date:  2009-11-09       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.